Immunome, Inc. announced the appointment of Jean-Jacques ?JJ? Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.

Mr. Bienaimé currently serves as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals, Inc., a position that he has held since 2005. Under Mr. Bienaimé?s leadership, BioMarin grew from a company with a single marketed treatment product to a multi-billion-dollar commercial organization with numerous approved products to treat rare diseases, increasing the company?s value from approximately $400 million to approximately $15 billion. It has been announced that Mr. Bienaimé will transition to retirement from his role as Chairman and Chief Executive Officer of BioMarin effective December 1, 2023.

Prior to joining BioMarin, Mr. Bienaimé served as the Chairman, President and Chief Executive Officer of Genencor, a targeted oncology biopharmaceutical company that was ultimately acquired in 2005 by Danisco. Prior to Genencor, Mr. Bienaimé held the positions of Chairman, President and Chief Executive Officer of Sangstat Medical. During his time at Sangstat Medical, Mr. Bienaimé guided the company to profitability, prior to an eventual acquisition by Genzyme.

Prior to joining Sangstat Medical, Mr. Bienaimé held various senior management positions at Rhone-Poulenc Rorer Pharmaceuticals and Genentech. Mr. Bienaimé currently serves on the Board of Directors of Incyte Corp., a biopharmaceutical company focused on first-in-class treatments for serious unmet needs, the Pharmaceutical Research and Manufacturers of America organization (PhMRA) and The Biotech Industry Organization (BIO). Mr. Bienaimé received his MBA from the Wharton School at the University of Pennsylvania and his undergraduate degree from the École Supérieure de Commerce de Paris.